Century Therapeutics Debt-to-Equity Ratio Growth & History (IPSC)
Century Therapeutics's debt-to-equity ratio was 0.27 for fiscal 2025.
View full Century Therapeutics company overviewCentury Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.27 | −0.06 | −17.83% |
| 2024 | 2024-12-31 | 0.33 | 0.07 | +27.94% |
| 2023 | 2023-12-31 | 0.26 | 0.10 | +59.74% |
| 2022 | 2022-12-31 | 0.16 | 0.10 | +157.51% |
| 2021 | 2021-12-31 | 0.06 | — | — |
Century Therapeutics quarterly debt-to-equity ratio
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.17 | −0.08 | −32.15% |
| Q1 2026 | 2026-03-31 | 0.18 | −0.04 | −17.20% |
| Q4 2025 | 2025-12-31 | 0.27 | −0.06 | −17.83% |
| Q3 2025 | 2025-09-30 | 0.25 | −0.02 | −8.63% |
| Q2 2025 | 2025-06-30 | 0.25 | −0.01 | −3.37% |
| Q1 2025 | 2025-03-31 | 0.22 | −0.04 | −16.13% |
| Q4 2024 | 2024-12-31 | 0.33 | 0.07 | +27.94% |
| Q3 2024 | 2024-09-30 | 0.28 | 0.06 | +28.56% |
| Q2 2024 | 2024-06-30 | 0.25 | 0.08 | +49.56% |
| Q1 2024 | 2024-03-31 | 0.26 | 0.07 | +39.12% |
| Q4 2023 | 2023-12-31 | 0.26 | 0.10 | +59.74% |
| Q3 2023 | 2023-09-30 | 0.22 | 0.07 | +51.59% |
| Q2 2023 | 2023-06-30 | 0.17 | 0.05 | +47.27% |
| Q1 2023 | 2023-03-31 | 0.19 | 0.12 | +189.95% |
| Q4 2022 | 2022-12-31 | 0.16 | 0.10 | +157.51% |
| Q3 2022 | 2022-09-30 | 0.14 | 0.08 | +139.77% |
| Q2 2022 | 2022-06-30 | 0.12 | 0.06 | +105.22% |
| Q1 2022 | 2022-03-31 | 0.06 | — | — |
| Q4 2021 | 2021-12-31 | 0.06 | — | — |
| Q3 2021 | 2021-09-30 | 0.06 | — | — |
| Q2 2021 | 2021-06-30 | 0.06 | — | — |
Century Therapeutics debt-to-equity ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, Century Therapeutics's debt-to-equity ratio increased from 0.06 to 0.27, a change of 0.21. The latest reported quarter, Q2 2026, shows 0.17.
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Century Therapeutics source filings ↗